

# **Technical Review Panel Member**

## Curriculum Vitae

Name: Colleen Daniels
Nationality: South African and Australian

Additional languages:

Expertise: Human rights, gender, TB, HIV, harm reduction

## **Qualifications**

Qualification	Institution	Department	Year
MA	University of Melbourne	International	1998
		Relations	
BA	St. Mary's University	International	1996
		Relations	
	Graduate Certificate III, Public		1998
	Administration, Public Service &		
	Merit Protection Commission,		
	Canberra, Australia		

# **Employment History**

Employer	Position	Place	Year
Harm Reduction	Deputy Director/Public Health	London, UK	2020
International	Lead		
CD Global Consulting	Consultant	Global	2017-2020
Stop TB Partnership	Human Rights and Gender	Geneva,	2015-2017
(UNOPS)	Advisor	Switzerland	
Treatment Action	Director TB/HIV	New York, USA	2012-2015
Group			
World Health	TB/HIV Technical Officer	Geneva,	2007-2011
Organization		Switzerland	
Health Action	Program Coordinator	Amsterdam,	2004-2007
International		The	
		Netherlands	
		Nairobi, Kenya	
		Bangkok,	
		Thailand	

World Vision Australia	Research and Campaigns Officer, HIV	Melbourne, Australia	2002-2004
AusAID	Youth Ambassador	Ha'apai, Kingdom of Tonga	2000-2001
Commonwealth Department of Immigration	Policy Officer	Canberra, Australia	1998-2000

### **Relevant Publications**

- Shirley-Beavan, S., Roig, A., Burke-Shyne, N. et al. Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. Harm Reduct J 17, 78 (2020). https://doi.org/10.1186/s12954-020-00429-5
- 2. Daniels C., Citro B., Maleche A., Why People Failing their TB Treatment Should Not Be Jailed. <a href="https://bhekisisa.org/article/2018-03-23-00-why-human-rights-should-be-built-into-tb-responses">https://bhekisisa.org/article/2018-03-23-00-why-human-rights-should-be-built-into-tb-responses</a>
- 3. Daniels C., Helen S Cox., Jennifer J Furin., Carole D Mitnick., Vivian Cox., Eric Goemaere. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bulletin of the World Health Organization 2015;93:491-497. doi: http://dx.doi.org/10.2471/BLT.14.138925
- Daniels C., Houben R., Nicolas A Menzies, Tom Sumner, Grace H Huynh, Michael E Kimerling, Anna Vassall. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health. Volume 4, Issue 11, PE806-E815, November 01, 2016.
- Daniels C., Houben R., Nicolas A Menzies, Tom Sumner, Grace H Huynh, Michael E Kimerling, Anna Vassall. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health. Volume 4, Issue 11, November 2016, Pages e816-e826
- 6. open access.
- 7. Daniels C., William Wells, Catharina Boehme. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. The Lancet Infectious Diseases. Volume 13, Issue 5, May 2013, Pages 449-458
- 8. Daniels C., In Access to new medications for the treatment of drugresistant tuberculosis: Patient, provider and community perspectives. Lessem E., Cox H., Furin J., McKenna L., Mitnick C., Mosidi T., Reed C., Seaworth B., Stillo., Tisile P., Delft D. International Journal of Infectious Diseases. <u>Volume 32</u>, March 2015, Pages 56–60
- 9. Daniels C., <u>In Tuberculosis Medicines Technology and Market Landscape</u> 2014. UNITAID
- 10. Daniels, C. (2014, July). The Tuberculosis Diagnostics Pipeline. In Clayden, P., Collins, S., Daniels, C., Frick M., Harrington, M., Horn, T.,

- Jefferys, R., Kaplan, K., Lessem, E., McKenna L., Swan, T. 2014 Pipeline Report: HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development (pp. 183-196). New York, NY:I-BASE and Treatment Action Group (TAG)
- 11. Daniels C., <u>Epidemic: Killer TB Spreads As Research Plummets</u> (Op-Ed). <u>http://www.livescience.com</u> Oct, 17 2014
- 12. Daniels. C. (2013, June). The Tuberculosis Treatment Pipeline. In Clayden, P., Collins, S., Daniels, C., Geffen, N., Harrington, M., Horn, T., Jefferys, R., Kaplan, K., Lessem, E., Swan, T. 2013 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development (pp. 217-250). New York, NY: I-BASE and Treatment Action Group (TAG).
- 13. McKenna, L., Van Doren, V., Tolman, A., Lessem, E., Daniels, C., Furin, J., Becerra, M., Brigden, G., Colorado, A. (Eds.) (2013). We Can Heal—Prevention, Diagnosis, Treatment, Care, and Support: Addressing Drug-Resistant Tuberculosis in Children. Boston, MA: The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Retrieved from http://sentinelproject.files.wordpress.com/2013/03/sentinel\_project\_we\_c an\_heal\_20131.pdf
- 14. Wingfield, C., Syed, J., Lessem, E., Harrington, M., Daniels, C. (2013, February). *Tuberculosis Medicines Landscape Report*. Geneva, CH: UNITAID. Retrieved from http://www.unitaid.eu/images/marketdynamics/publications/TB%20Medicines%20Tech.%20Landscap e\_Final.pdf
- 15. World Health Organization, CDC, UNICEF, The Union, Stop TB Partnership, USAID, TAG. Roadmap for Childhood TB: Toward Zero Deaths. Geneva, CH. Retrieved from: <a href="http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137\_eng.pdf">http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137\_eng.pdf</a>
- 16. Wells. W., Boehme MD, C., Cobelens F., Daniels, C., Dowdy, D., Gardiner, E., Gheuns, J., Kim, P., Kimmerling, M., Kreiswirth, B., Lienhardt, C., Mdluli, K., Pai, M., Perkins, M., Peter, T., Zignol, M., Zumla, A., Schito, M. (May 2013). <u>Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action</u>. The Lancet Infectious Diseases, Vol. 13 No. 5 pp 449-458.
- 17. McKenna, L., Daniels, C., (November 2013). *Urgency Needed in the Global Response to Drug-resistant Tuberculosis*. Speaking of Medicine Blog. Retrieved from: <a href="http://blogs.plos.org/speakingofmedicine/2013/11/01/urgency-needed-in-the-global-response-to-drug-resistant-tuberculosis/">http://blogs.plos.org/speakingofmedicine/2013/11/01/urgency-needed-in-the-global-response-to-drug-resistant-tuberculosis/</a>
- 18. Amitabh B. Suthar, <sup>1</sup> Eveline Klinkenberg, <sup>2</sup> Andrew Ramsay, <sup>3</sup> Navneet Garg, <sup>4</sup> Rod Bennett, <sup>5</sup> Megan Towle, <sup>1</sup> Joseph Sitienei, <sup>6</sup> Caoimhe Smyth, <sup>1</sup> Colleen Daniels, <sup>7</sup> Rachel Baggaley, <sup>1</sup> Christian Gunneberg, <sup>7</sup> Brian Williams, <sup>8</sup> Haileyesus Getahun, <sup>7</sup> Jeroen van Gorkom, <sup>2</sup> Reuben M. Granich <sup>1</sup> <u>Community-based multi-disease prevention campaigns for controlling HIV-associated tuberculosis.</u> International Journal of Tuberculosis and Lung Disease. Volume 16, Number 4, 1 April 2012, pp. 430-436(7)

- 19. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. (2009).
- 20. Daniels C., Gunneberg C., and Reid A., <u>From Mekong to Bali: The scale up of TB/HIV collaborative activities in Asia Pacific [1Mb]</u> Report of the meeting organized by the World Health Organization in collaboration with the TB/HIV Working Group of the Stop TB Partnership. 2009.

#### Additional Information

Colleen is the Deputy Director and Public Health Lead at Harm Reduction International. She has 23 years' experience as a Director, Project Manager, and Technical Advisor in HIV/AIDS, tuberculosis, gender, human rights, challenging operating environments, and community systems strengthening, working to deliver access to essential health services. She has worked in programs globally and has lived and worked in Australia, Kenya, the Netherlands, Switzerland, Thailand, the Kingdom of Tonga and the USA.

Colleen has successfully worked in a variety of settings, including the UN agencies Stop TB Partnership (UNOPS), World Health Organization (WHO), international NGOs Treatment Action Group, Health Action International (HAI), and the Tongan and Australian Governments (Department of Immigration and AusAID). She initiated the global strategy on TB and human rights and worked with TB and HIV civil society to increase their capacity to engage with the Global Fund, UN agencies, donors and governments. She also worked to catalyse global leadership to accelerate momentum toward universal access for high-quality TB and TB/HIV services; and to accelerate funding and progress in R&D for better tools to prevent, diagnose, and treat TB. While at WHO, Colleen was responsible for developing and implementing advocacy campaigns and communications strategies to accelerate TB/HIV service delivery in developing countries. She is a current member of the Technical Review Panel for the Global Fund to Fight AIDS, Tuberculosis, and Malaria.